# Junta clínica — PT-pseudo_f4ea752ca1bb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f4ea752ca1bb",
  "pid": "PT-pseudo_f4ea752ca1bb",
  "task": 1,
  "psa": 6.9,
  "age": 79,
  "months": 1,
  "pirads": "4",
  "psad": 0.159,
  "psav": 1.53,
  "psap": 6.6,
  "vol": 43.34,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.7682602,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 43 mL. DRE nodus. csPCa 0.77.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "188 cm",
    "bmi": "23.8",
    "bp": "125/84 mmHg",
    "hr": "75 bpm",
    "smoking": "Current smoker (15 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "21 Jan 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation of the prostate-specific antigen level to 6.9 ng/mL prompted this consultation after recent multiparametric imaging."
    },
    {
      "s": "History",
      "t": "A 79-year-old retired civil servant entered the system in spring 2023 after an initial prostate-specific antigen reading of 3.7 ng/mL. Surveillance has continued given the steady upward trend. Following the passing of his spouse several years prior, he now resides solo, depending on his daughter for mail handling while maintaining full independence in daily routines. Lower urinary tract complaints remain slight, reflected by an IPSS score of 3. Respiratory management involves tiotropium alongside salbutamol administered as required for his COPD. Beyond urological matters, he recently finished a standard colonoscopy screening and visited vascular surgery regarding asymptomatic varicose veins. Daily gardening sustains his activity level, he completely avoids alcohol, and maintains a current smoking status with a 15 pack-year history. He explicitly denies haematuria, unexplained weight loss, or bone pain."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, mobility: fixed, asymmetry: prominent. A discrete nodule resides within the right posterior peripheral zone, accompanied by overall gland enlargement. General assessment shows clear lung fields and a regular cardiac rhythm. Blood pressure registers at 125/84 mmHg, with a heart rate of 75 bpm."
    }
  ],
  "occupation": "retired civil servant",
  "marital": "Widowed",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 3/35 (mild LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f4ea752ca1bb
Task: 1

Encounter: Urology - outpatient on 21 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 79-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.159 ng/mL²
  - PSA velocity: 1.53 ng/mL/yr
  - Prior PSA: 6.6 ng/mL
  - Prostate volume: 43.34 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7682602 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 43 mL. DRE nodus. csPCa 0.77.

Vitals: weight 84 kg, height 188 cm, BMI 23.8, BP 125/84 mmHg, HR 75 bpm. Smoking: Current smoker (15 pack-yr).

Chief complaint: Persistent elevation of the prostate-specific antigen level to 6.9 ng/mL prompted this consultation after recent multiparametric imaging.

History: A 79-year-old retired civil servant entered the system in spring 2023 after an initial prostate-specific antigen reading of 3.7 ng/mL. Surveillance has continued given the steady upward trend. Following the passing of his spouse several years prior, he now resides solo, depending on his daughter for mail handling while maintaining full independence in daily routines. Lower urinary tract complaints remain slight, reflected by an IPSS score of 3. Respiratory management involves tiotropium alongside salbutamol administered as required for his COPD. Beyond urological matters, he recently finished a standard colonoscopy screening and visited vascular surgery regarding asymptomatic varicose veins. Daily gardening sustains his activity level, he completely avoids alcohol, and maintains a current smoking status with a 15 pack-year history. He explicitly denies haematuria, unexplained weight loss, or bone pain.

Physical examination: DRE — texture: firm, mobility: fixed, asymmetry: prominent. A discrete nodule resides within the right posterior peripheral zone, accompanied by overall gland enlargement. General assessment shows clear lung fields and a regular cardiac rhythm. Blood pressure registers at 125/84 mmHg, with a heart rate of 75 bpm.

Patient info: retired civil servant; Widowed; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 3/35 (mild LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Vascular surgery — varicose veins consult.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.68
  uncertainty  +/- 0.08 epistemic (95% band 0.52-0.85); among patients I cannot tell apart the outcome was 0.90 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.88: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."
  2. distance 2.16: PI-RADS 4, PSA 4.8, PSAD 0.086, age 65, DRE Nodus -> BIOPSY (clear). He wrote: "P4 in patient 65 years."
  3. distance 2.56: PI-RADS 4, PSA 9.3, PSAD 0.296, age 66, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 66 year old patient."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. The guideline states, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline makes the PI-RADS score decisive, and the patient has a PI-RADS 4 lesion. EXPERT-COHORT, I agree with the criterion because the cohort confirms that sampling when the mpMRI shows a PI-RADS 3 or higher lesion is the correct approach for this situation.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None means the guideline suggests sampling when PI-RADS $\ge 3$ is the trigger.
radiology_report - whether the lesion is compared against an earlier study: this is not specified, but the PI-RADS 4 score is the key factor.
psa_trend - the PSA velocity is $1.53 \text{ ng/mL/yr}$, which is a factor in risk stratification but the guideline does not explicitly state a threshold for biopsy based on velocity alone.
laboratory_results - the PSA density is $0.159 \text{ ng/mL/cc}$, which is a factor in risk stratification but the guideline does not explicitly state a threshold for biopsy based on PSA density alone.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 4 finding, in the absence of prior biopsy, is sufficient to trigger a biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the implication of the PSA velocity ($1.53 ext{ ng/mL/yr}$) for biopsy decision-making.
  previous_notes (get_previous_notes) -> Determine the prior biopsy status, surveillance protocol, and planned management.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend reveal about the risk stratification beyond the velocity value?
  Q3. What does the previous_notes state regarding the prior biopsy status, surveillance protocol, and planned management?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "focal hypointense area within the right posterior peripheral zone at the base, spanning approximately 18 x 14 x 16 mm."

psa_trend
The psa_trend reveals a rising trend from 2.0 (Apr 2023) to 6.9 (Jan 2025), with the velocity being $1.53 \text{ ng/mL/yr}$ between the last two recorded points.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: None
SURVEILLANCE: Surveillance has continued given the steady upward trend.
TREATMENT: none recorded

WHAT I DID NOT OPEN
I did not open the laboratory_results because the PSA density was noted but its specific implication for the biopsy decision was not explicitly detailed in the retrieved information.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 4 lesion is present, which is a trigger according to the EAU guideline.
Prior biopsy status is None, meaning the patient is biopsy-naive.

AGAINST sampling this patient now
Nothing

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.90 ng/mL over 4 points spanning 21 months; velocity +2.79 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 3.0-36.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.84), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.68  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered all the moderator's questions. The `radiology_report` addressed Q1 by stating "COMPARISON: new," the `psa_trend` addressed Q2 by showing the rising trend and velocity, and the `previous_notes` addressed Q3 by stating "BIOPSY SESSIONS: None" and "SURVEILLANCE: Surveillance has continued given the steady upward trend."

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the `radiology_report` confirms a PI-RADS 4 lesion, which is the rule that fired the cohort criterion, and the `previous_notes` confirm the patient is biopsy-naive.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study? The report states "COMPARISON: new."
Q2. What does the psa_trend reveal about the risk stratification beyond the velocity value? The trend shows a rise from 2.0 to 6.9 over 21 months with a velocity of $1.53 \text{ ng/mL/yr}$.
Q3. What does the previous_notes state regarding the prior biopsy status, surveillance protocol, and planned management? The notes state "BIOPSY SESSIONS: None" and "SURVEILLANCE: Surveillance has continued given the steady upward trend."

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 4 is the most critical variable as it directly triggers the cohort criterion, which the panel protocol confirms as the deciding rule. The lack of a prior biopsy is also highly weighted as it places the patient in the biopsy-naive category, which the cohort criterion specifically targets.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the alignment between the PI-RADS 4 finding and the cohort criterion, which is supported by the retrieved information confirming the patient is biopsy-naive.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

79 y/o male, PSA 6.9 ng/mL, PSAD 0.159, biopsy-naive, PI-RADS 4. Biopsy is indicated due to PI-RADS 4 and rising PSA density, which is a new finding. No prior pathology to contraindicate sampling.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
